Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Visceral Pain
|
0.200 |
Biomarker
|
phenotype |
RGD |
A rat knockout model implicates TRPC4 in visceral pain sensation.
|
24388923 |
2014 |
Diastolic blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk.
|
28135244 |
2017 |
Esophageal Neoplasms
|
0.100 |
GeneticVariation
|
group |
GWASDB |
Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions.
|
22960999 |
2012 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
TRPC4/TRPC5 channels mediate adverse reaction to the cancer cell cytotoxic agent (-)-Englerin A.
|
30038709 |
2018 |
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
TRPC4/TRPC5 channels mediate adverse reaction to the cancer cell cytotoxic agent (-)-Englerin A.
|
30038709 |
2018 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The sesquiterpene (-)Englerin A (EA) is an organic compound from the plant Phyllanthus engleri which acts via heteromeric TRPC4/C1 channels to cause cytotoxicity in some types of cancer cell but not normal cells.
|
29209034 |
2017 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
(-)-Englerin A ((-)-EA) has a rapid and potent cytotoxic effect on several types of cancer cell that is mediated by plasma membrane ion channels containing transient receptor potential canonical 4 (TRPC4) protein.
|
27875305 |
2017 |
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
The sesquiterpene (-)Englerin A (EA) is an organic compound from the plant Phyllanthus engleri which acts via heteromeric TRPC4/C1 channels to cause cytotoxicity in some types of cancer cell but not normal cells.
|
29209034 |
2017 |
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
(-)-Englerin A ((-)-EA) has a rapid and potent cytotoxic effect on several types of cancer cell that is mediated by plasma membrane ion channels containing transient receptor potential canonical 4 (TRPC4) protein.
|
27875305 |
2017 |
Hodgkin Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
In accordance, cortisol level tended to be higher in fish fed both supplemented diets at LD compared to fish fed CTRL, but was lower in fish fed TRP4 than in those fed TRP2 under HD condition.
|
31118899 |
2019 |
Huntington Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
In accordance, cortisol level tended to be higher in fish fed both supplemented diets at LD compared to fish fed CTRL, but was lower in fish fed TRP4 than in those fed TRP2 under HD condition.
|
31118899 |
2019 |
Triple Negative Breast Neoplasms
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
BT-549 and Hs578T cells express high levels of TRPC4 and TRPC1/4, respectively, and are exquisitely, 2000- and 430-fold, more sensitive to englerin A than other TNBC cell lines.
|
31230251 |
2019 |
Right Ventricular Hypertrophy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Ca<sup>2+</sup> handling remodeling and STIM1L/Orai1/TRPC1/TRPC4 upregulation in monocrotaline-induced right ventricular hypertrophy.
|
29634917 |
2018 |
Psychiatric symptom
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Together, this experimental data set introduces a novel, high quality, small molecule antagonist of TRPC4 and TRPC5 containing channels and supports the targeting of TRPC4 and TRPC5 channels as a new mechanism of action for the treatment of psychiatric symptoms.
|
29385160 |
2018 |
Congenital Hyperinsulinism
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, these studies demonstrate a critical role for PHPT-1 in normal pancreatic β-cell function and raise the possibility that mutations in PHPT-1 and/or TRPC4 may account for yet to be defined cases of CHI.
|
29440278 |
2018 |
Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that OGR1 enhances expression of TRPC4-containing channels that contribute to enhanced invasion and metastasis of granule precursor-derived human medulloblastoma.
|
28627017 |
2017 |
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Our results suggest that OGR1 enhances expression of TRPC4-containing channels that contribute to enhanced invasion and metastasis of granule precursor-derived human medulloblastoma.
|
28627017 |
2017 |
Tuberous Sclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our results indicate that overexpression of TRPC4 protein may be involved in the epileptogenesis of FCD II and TSC.
|
28455787 |
2017 |
Childhood Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that OGR1 enhances expression of TRPC4-containing channels that contribute to enhanced invasion and metastasis of granule precursor-derived human medulloblastoma.
|
28627017 |
2017 |
Adult Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that OGR1 enhances expression of TRPC4-containing channels that contribute to enhanced invasion and metastasis of granule precursor-derived human medulloblastoma.
|
28627017 |
2017 |
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Our results suggest that OGR1 enhances expression of TRPC4-containing channels that contribute to enhanced invasion and metastasis of granule precursor-derived human medulloblastoma.
|
28627017 |
2017 |
Focal cortical dysplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Elevated Expression of TRPC4 in Cortical Lesions of Focal Cortical Dysplasia II and Tuberous Sclerosis Complex.
|
28455787 |
2017 |
Cerebellar medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
OGR1 and TRPC4 are prominently expressed in healthy cerebellar tissue throughout postnatal development and in primary cerebellar medulloblastoma tissues.
|
28627017 |
2017 |
Malignant Head and Neck Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
TRPC4 was found to be closely associated with incidence of head and neck cancer and poor survival of patients with kidney cancer.
|
26708603 |
2016 |